<DOC>
	<DOC>NCT00717990</DOC>
	<brief_summary>This study will evaluate the efficacy of Irinotecan,Capecitabine and Avastin combination in patients with no response to previous treatment with 5-Fluorouracil,Leucovorin,Eloxatin and Avastin.</brief_summary>
	<brief_title>Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment</brief_title>
	<detailed_description>The aim of this phase II study is to evaluate the efficacy of the combination XELIRI/AVASTIN in patients with mCRC, who have progressed in first line treatment with FOLFOX/AVASTIN. For AVASTIN was selected the dosing schedule of the trials TREE 1 and 2 [17], where Avastin was combined with capecitabine and oxaliplatin in a three weeks schedule and with adaptation of the dose in the 7,5 mg/kg</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically confirmed locally advanced or metastatic colorectal cancer Measurable or evaluable disease according to the Response Evaluation Criteria in Solid Tumors ECOG performance status ≤ 2 Age 18 72 years Patients who progress after 1st line therapy with FOLFOX/AVASTIN Adequate liver (Bilirubin ≤ 1.5 upper normal limit, SGOT/SGPT ≤ 4 upper normal limit, ALP ≤ 2.5 upper normal limit) renal (Creatinine ≤ 1.5 upper normal limit) and bone marrow (ANC ≥ 1,500/mm3, PLT ≥100,000/mm3) function Patients must be able to understand the nature of this study Written informed consent History of serious cardiac disease (unstable angina, congestive heart failure,uncontrolled cardiac arrhythmias) History of myocardial infarction or stroke within 6 months Clinically significant peripheral vascular disease History of abdominal fistula, gastrointestinal perforation or intraabdominal abscess within 28 days prior to Day 0 Major surgical procedure, open biopsy, or significant traumatic injury within 30 days prior to Day 1 Presence of central nervous system or brain metastasis Evidence of bleeding diathesis or coagulopathy Blood pressure &gt; 150/100 mmHg Pregnant or lactating woman Life expectancy &lt; 3 months Previous radiotherapy within the last 4 weeks or &gt; 25% of bone marrow Metastatic infiltration of the liver &gt; 50% Patients with chronic diarrhea (at least for 3 months) or partial bowel obstruction or total colectomy Active infection requiring antibiotics on Day 1 Second primary malignancy, except for nonmelanoma skin cancer and in situ cervical cancer Psychiatric illness or social situation that would preclude study compliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>XELIRI</keyword>
</DOC>